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Background: Stage III N2 non-small cell lung cancer (NSCLC) is a very heterogeneous disease associated 
with a poor prognosis. A number of therapeutic options are available for patients with Stage III N2 NSCLC, 
including surgery [with neoadjuvant or adjuvant chemotherapy (CTx)/neoadjuvant chemoradiotherapy 
(CRT)] or CRT potentially followed by adjuvant immunotherapy. We have no clear evidence demonstrating 
a significant survival benefit for either of these approaches, the selection between treatments is not always 
straightforward and can come down to physician and patient preference. The very heterogeneous definition 
of resectability of N2 disease makes the decision-making process even more complex. 
Methods: We evaluated the treatment strategies for preoperatively diagnosed stage III cN2 NSCLC among 
Swiss thoracic surgeons and radiation oncologists. Treatment strategies were converted into decision trees 
and analysed for consensus and discrepancies. We analysed factors relevant to decision-making within these 
recommendations. 
Results: For resectable “non-bulky” mediastinal lymph node involvement, there was a trend towards 
surgery. Numerous participants recommend a surgical approach outside existing guidelines as long as 
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Introduction
Stage III non-small cell lung cancer (NSCLC) with 
subcarinal and/or ipsilateral mediastinal lymphatic spread 
(N2, TNM UICC 8th edition) may be treated with curative 
intent. However, treatment outcome remains poor with 15–
50% 5-year overall survival (OS) rates (1-4). The optimal 
treatment for potentially resectable N2 NSCLC patients 
is unclear due to the heterogeneity of the disease, a lack 
of a universal definition of resectability, and comparable 
outcomes with different treatment approaches. There is a 
variety of factors influencing the availability and suitability 
of various treatments (5) and a large number of clinical 
decision criteria used in daily decision-making (6). The 
two main multimodal treatment options for NSCLC N2 
disease are surgery (with neoadjuvant chemotherapy (CTx)/
chemoradiotherapy (CRT) or combined with adjuvant CTx) 
or CRT [with or without adjuvant immunotherapy (7)]. 
Both treatment options may be available for several 
decision criteria combinations, especially since there is no 
randomised evidence suggesting a clear survival benefit 
with one approach over another (4,8,9). This is reflected in 
international guidelines where radiotherapy and surgery are 
both options for selected stage III N2 NSCLC, especially in 
cases with limited lymph node involvement (10,11). In such 
a setting, patient preference becomes even more relevant 
and the focus may shift away from OS towards side effects, 
quality of life and logistical issues (e.g., hospital stay for 
surgery or receiving daily outpatient treatments for several 
weeks with radiotherapy). 
In daily clinical routine, there are scenarios where 
multiple treatment options are available. It is important to 
recognize these situations for an optimal shared decision-
making approach. The aim of this work was to identify 
which disease characteristics are applied in current clinical 
practice among Swiss thoracic oncology centres for stage 
III N2 NSCLC and how they impact decision-making in 
clinical routine.
Methods
All Swiss centres providing both departments for thoracic 
surgery and radiation oncology with an established training 
program were asked to participate in this study. The initial 
search for qualifying centres was performed in October 
2018 according to the list of the Swiss Institute for Medical 
Education (SIWF). Twelve centres were identified. The 
head of each radiation oncology and thoracic surgery 
department was asked to describe her or his practice in 
preoperatively diagnosed stage III N2 NSCLC. In some 
instances, a senior physician specialized in lung cancer 
represented the department. The collected answers from 11 
surgeons and 12 radiation oncologists were anonymously 
analysed, one expert declined to participate. All university 
hospitals as well as most Swiss cantonal hospitals were 
represented.
All participating centres were asked to provide their 
recommendations and decision criteria for the management 
of preoperatively diagnosed stage III N2 NSCLC. 
The recommendations were reduced to the options 
of: a definitive surgical approach (with neoadjuvant or 
adjuvant CTx/CRT), definitive CRT approach or “patient 
preference” (no specific recommendation for either 
RT or surgery; both being options). Decision criteria 
collected were converted into decision trees, analysed and 
standardized if their meaning was not changed as described 
previously (12-14). For better comparison, universal criteria 
the disease was resectable, even in multilevel N2. With increasing extent of mediastinal nodal disease, 
multimodal treatment based on radiotherapy was more common. 
Conclusions: Both, surgery- or radiotherapy-based treatment regimens are feasible options in the 
management of Stage III N2 NSCLC. The different opinions reflected in the results of this manuscript 
reinforce the importance of a multidisciplinary setting and the importance of shared decision-making with 
the patient.
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such as “ability to give informed consent” were not included 
in this analysis. In several instances, trial participation was a 
recommended option. This was excluded from the decision 
tree analysis, as trials are considered experimental and 
potentially not applicable to the routine clinical setting.
The resulting decision criteria included: resectability 
(potentially resectable or not), lymph node (LN) volume 
(bulky, non-bulky), and LN extent (single station, multi 
station and single zone, multi-zone). For the purpose of this 
analysis, “resectability” included the possibility of surgical 
tumour removal with an R0 margin based on preoperative 
imaging, as well as the required physical fitness for radical 
operative treatment. 
The extent of mediastinal lymph node involvement 
was categorized as: (I) single station and therefore single 
zone; (II) multi-station but limited to single zone; and 
(III) multi-zone. This was in-line with the descriptions 
received from individual participants and was based on a 
previous analysis of international guidelines (11). In the 
British Thoracic Society (BTS) (15) and Irish guidelines 
(16) lymph nodes are grouped by zones according to the 
IASLC lymph node map (AJCC 7th edition), whereas most 
others, e.g., ESMO (10,17) or German (18) guidelines 
used nodal stations.
The descriptions used to characterise mediastinal 
lymph nodes varies among guidelines (11). Non-bulky 
lymph nodes are mostly described as lymph nodes with 
a diameter of less than 3 cm short-axis diameter, easily 
measurable and free of major mediastinal structures 
including the trachea and great vessels, or low volume 
lymph nodes (15,19-22). Many experts described bulkiness 
or size of lymph nodes, while no specific cut-off in cm was 
defined, these criteria were simplified and represented as 
“bulky vs. non-bulky”.
As the treatment of stage III N2 NSCLC is multimodal 
(11,23-26), the reduction to radiotherapy or surgery-
based treatments represents a significant simplification. 
For multimodal treatment based on a surgical approach, 
no distinction was made between neoadjuvant and adjuvant 
chemotherapy (19,20). 
Statistical analysis 
The resulting decision trees were analysed for consensus 
and discrepancies with the objective consensus methodology 
(12,27,28). Majorities were calculated by dividing the most 
common recommendation for any specific situation by the 
number of participants.
Results
Twenty-three management strategies with recommendations 
for all unified decision criteria were identified and converted 
into decision trees. An example of a single decision tree is 
shown in Figure 1. 
The three major decision criteria that affected treatment 
decisions were resectability, bulkiness of lymph nodes and 
lymph node extent. The three simplified treatment options 
included surgery, radiotherapy, and patient preference. 
For non-resectable cases, radiotherapy-based treatments 
were recommended by all experts. 
For patients with non-bulky lymph nodes a majority 
recommended surgery. In case of single-station non-bulky 
disease, 91% of experts recommended surgery as the single 
most common recommendation. In case of multi-station, 
but single-zone disease, still 83% recommended surgery as 
the single most common recommendation. For multi-zone 
non-bulky disease, a slight majority (65%) for surgery was 
identified with 7 experts (30%) stating radiotherapy and one 
(4%) stating patient preference as their recommendation 
(Figure 2).
In bulky disease, the majority (74–83%, dependant on LN 
extent) recommended radiotherapy; however, for example 
in single-station disease, five experts (22%) recommended 
surgery and one (4%) recommended patient preference. In 
cases where surgery was recommended for bulky disease 
comment was added by the experts that a neoadjuvant 
approach (with chemotherapy or radio-chemotherapy) was 
Figure 1 Example of the simplified decision tree. LN, lymph nodes; OP, surgery; RT, radiotherapy.
1963Translational Lung Cancer Research, Vol 10, No 4 April 2021
© Translational Lung Cancer Research. All rights reserved.   Transl Lung Cancer Res 2021;10(4):1960-1968 | http://dx.doi.org/10.21037/tlcr-20-1210
recommended and that the surgery would be performed only 
if a good response was observed (Figures 2-4).
Patient preference as a recommendation only occurred 
in 4 settings, this included 2 radiation oncologists and 
two surgeons in various situations (Figures 3,4). A trend 
towards radiotherapy among radiation oncologists and 
surgery among thoracic surgeons was observed (Figures 2,3). 
Seventy-three percent of participating surgeons would 
recommend a surgical approach and 18% would recommend 
CRT in resectable, non-bulky, multizone stage III N2 
NSCLC, whereas 42% of radiation oncologists would 
recommend CRT for the same condition and surgery in 58%.
Discussion
Our decision-making analysis revealed surgery-based 
approaches as  the most commonly recommended 
treatments for resectable stage III N2 NSCLC, with a 
Figure 2 demonstrates the overall majority recommendations for each parameter combination. LN, lymph nodes; OP, surgery; RT, 
radiotherapy.
Figure 3 Demonstrates the answers from the radiation oncologists for all combinations of simplified criteria. Single alphabetic letters: 
participating sites. LN, lymph nodes; OP, surgery; PP, patient’s preference; RT, radiotherapy.
Figure 4 Demonstrates the answers from surgeons for all combinations of simplified criteria. Single alphabetic letters: participating sites. 
LN, lymph nodes; OP, surgery; PP, patient’s preference; RT, radiotherapy.
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significant proportion of recommendations considering 
radiotherapy as an alternative. Overall, there was a stronger 
preference for surgical approaches the smaller the lymph-
node extent was (Figure 4). For non-resectable disease, there 
was a consensus for radiotherapy as well as a clear majority 
for radiotherapy in bulky disease.
Resectability is a prerequisite for surgery in stage III 
N2 NSCLC. Preoperative surgical evaluation can be 
challenging and dependent on the individual surgeon’s 
expertise. Universally agreed-upon criteria to guarantee the 
resectability of disease are lacking. Additionally preoperative 
and postoperative findings may diverge (29). The difficulty in 
standardization lies in the surgeon’s individual judgement on 
being able to achieve a clear resection margin, the assessment 
of which may be particularly challenging in more centrally 
located tumours. The definition of an unresectable tumour 
in this analysis was left to the decision of multidisciplinary 
tumour boards and was highly variable among institutions.
Overall, with increasing volume or extent of N2 disease, 
there was an increasing trend towards therapy based on 
RT. There was no consensus on a unified cut off for nodal 
volume related to surgery. In patients with low volume 
(especially single station) mediastinal N2 disease surgery was 
the preferred recommendation. Some guidelines recommend 
surgery for N2 disease without additional risk factors (such 
as bulky disease or multi-station disease, e.g., ESMO) or 
mention both radiotherapy- or surgery-based options (e.g., 
NCCN) (10,30). In our analysis, 91% of participating sites 
recommended a multimodal treatment based on surgery 
for single station (single-zone) non-bulky stage III N2 
NSCLC, in two cases (9%) patients’ preference was stated 
(offering CRT as an equivalent option in this setting). 
The recommendation rate for surgery-based approaches 
decreased with increasing mediastinal lymph node 
involvement, nevertheless 83% of participating surgeons as 
well as 75% radiation oncologists still recommended surgery 
as an option for multi-station, but single zone stage III N2 
NSCLC. With multi-zone involvement, a slight preference 
for surgery could be shown (65%) even though this is not in-
line with most guidelines (11). In this setting, a discrepancy 
between specialties was visible with 42% of radiation 
oncologists recommending radiotherapy, while only 18% 
of surgeons would not recommend surgery in NSCLC with 
multi-zone non-bulky LN involvement. A minor limitation 
of our simplification is that the primary multi-station nodal 
involvement described in a guideline using nodal stations as 
a descriptor could fall within a single zone or multiple zones 
(e.g., stations 2 & 4 would be a single zone, stations 4 & 7 
would be multi-zone) 
A lack of a clear definition of bulky lymph nodes leads to 
potential bias. Some consider 3 cm as the critical diameter 
for bulky definition (11), some authors consider bulky N2 
disease as lymph nodes already greater than 2.5 cm in short 
axis (31). The preference of radiotherapy-based approaches 
increases when mediastinal lymph nodes present as bulky. 
For all settings with bulky lymph nodes, radiotherapy-based 
approaches were the most recommended treatment. The rate 
for recommending radiotherapy-based approaches in bulky 
disease increased from 74% for single-station to 78% for 
multi-station single zone and to 83% for multi-zone bulky 
lymph node involvement. This trend is clearly in line with 
guidelines advising against surgery in the presence of bulky 
lymph nodes. The individual experts recommending surgical 
approaches in this setting also recommended neoadjuvant 
chemotherapy or radiotherapy with the aim of downstaging 
and considered a good response as well as an expectation of 
an R0 resection to be prerequisites for surgery. However, with 
a neoadjuvant treatment approach the risk of mediastinal soft 
tissue fibrosis may increase and may complicate subsequent 
hilar and mediastinal dissections (31,32).
A meta-analysis including randomized studies comparing 
definitive radiochemotherapy versus surgery in stage III 
NSCLC (4) found no significant difference between bimodal 
treatments (surgery vs. radiotherapy based) related to overall 
survival. There was heterogeneity across studies at two years, 
resulting from the rate of pneumonectomies performed. 
The increased mortality following pneumonectomies 
however was not confirmed in other trials (3,33,34). Another 
previous meta-analysis by McElnay et al. (9) compared 
CRT and surgery versus definitive CRT. It combined 
data from the Intergroup 0139 trial (2) and a study from 
Sorensen et al. (35) comparing induction CTx followed by 
RT versus induction CTx followed by surgery followed by 
RT. Both studies were weighted equally in the analysis. The 
pooled HR for death in the surgery group was 0.87 (95% 
CI: 0.75 to 1.01; P=0.068) with no statistical evidence of 
heterogeneity (P=0.976). Trimodal therapy was associated 
with a trend towards improved survival compared to bimodal 
treatments. However, comparisons between surgery and RT 
are complicated by early perioperative mortality of surgical 
patients with potential advantages in survival later on (36).
The 2019 NICE guidelines cover the management of 
NSCLC. For potentially resectable stage III N2 NSCLC the 
guideline specifically recommended trimodality treatment 
for patients fit enough for multi-modality treatment 
(induction CRT followed by surgery) (37). This is a highly 
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significant change from previous NICE recommendations 
and a significant change in UK practice where only 1.1% 
of N2 patients currently receive trimodality treatment (38). 
The meta-analysis of the NICE guideline group compared 
CRT followed by surgery (CRS), CRT, and chemotherapy 
and surgery (CS). A statistically clear survival benefit could 
not demonstrate between treatment regimens, but there 
was a trend towards improved survival with CRS (in line 
with the trends from other meta-analyses). The PFS at 4 
& 5 years (high quality evidence) was improved in the CRS 
group with an average of 4.5 month compared to CRT/CS. 
There was less grade 3+ adverse events with CRS than with 
CR/CS. The guideline also undertook cost-effectiveness 
modelling concluding that CRT is more cost effective than 
CS [Incremental cost-effectiveness ratio (ICER) £53,000/
quality-adjusted life year (QALY)] and CRS is more cost 
effective than CRT (ICER £17,800/QALY). Even though the 
guideline recommended trimodality treatment, such practice 
would require careful and considered implementation 
within agreed protocols through high volume centres where 
outcomes are monitored closely. In our analysis only 2 of 23 
experts recommended trimodality treatment in their clinical 
routine.
Overall, the evidence in this setting has several severe 
limitations. A number of key trials (Intergroup/EORTC) 
date from a time before routine 18FDG-PET/CT, 
endoscopic nodal staging and advances in surgical and RT 
techniques are not accounted for. Some trials, such as the 
ESPATUE trial (3) had a heterogeneous study population 
(e.g., 1/3 of patients with T4 N0/1) further hampering 
definitive conclusions on the management of N2 disease. 
Over the past years, immunotherapy has changed the 
landscape for patients with stage III NSCLC. Also, in the 
management of stage III N2 NSCLC this approach is part 
of ongoing trials (NCT04202809, NCT04287894 and 
NCT04245514). The implementation of immunotherapy 
in international treatment guidelines is progressing, 
however has not directly affected the decision between 
surgical and RT-based approaches yet. In unresectable 
stage III N2 NSCLC treated with CRT, a significantly 
longer progression free survival (PFS) and OS was reached 
with the addition of maintenance durvalumab and this has 
become a recommended strategy in guidelines (7,39). 
There are also considerations of using immunotherapy 
in the neoadjuvant setting. A study by Bott et al. (40) 
demonstrated a major pathological response in 45% of 
patients treated with nivolumab upfront of surgery, this 
trial enrolled NSCLC stage I−IIIA. However, more than 
a half of the minimally invasive-intended operations were 
converted to thoracotomy due to hilar inflammation 
and fibrosis. While there was no operative mortality, 
perioperative morbidity was present and mostly due to 
atrial arrhythmia. Similar results were published by Forde 
et al., with major pathological response rates on histologic 
examination of around 45%. Interestingly only two 
patients had a radiologic partial response (41). It was due 
to postulated immune-cell infiltration into the tumour, 
rather than true tumour mass. The phase II trial by Sacha 
Rothschild et al. (42) also demonstrated a high response 
rate and a very encouraging 1-year event-free survival by 
addition of perioperative durvalumab to standard of care 
cisplatin/docetaxel. To define the role of neoadjuvant 
immunotherapy long-term follow-up of currently recruiting 
phase 3 studies such as NCT02998528 need to be evaluated. 
The evolution of future treatment strategies involving 
immunotherapy need further prospective studies to answer 
the question whether CRT with Immunotherapy is superior 
to multimodal treatment based on surgery in potentially 
resectable stage III N2 NSCLC.
As shared decision-making is a complex process with 
various potential pitfalls (43), patient preference will 
become increasingly helpful if more than one treatment 
regimen can be offered with comparable outcome (5,44,45). 
Patient preference was a primary recommendation in 
selected settings, mentioned only by a limited number 
of experts (these represented both specialities). Patient 
preference may be challenging in clinical practice as a 
multitude of emotions and biases influence shared decision-
making (43,46). This process is even further complicated 
by the limited availability of patient-relevant information—
such as detailed information from side effects from clinical 
trials in this setting (47). Potentially a third party acting as 
an intermediary between the specialists may be of value in 
providing an un-biased view (e.g., pneumologist or general 
practitioner).
The results of this analysis are based on the input 
of specific individual experts in Switzerland, yet it is 
improbable that the trends observed would be significantly 
different if other experts from Switzerland would have been 
selected. A specialty bias was visible with trends towards 
surgery among surgeons and radiotherapy among radiation 
oncologists, this only reinforces the need for such analyses 
to be performed in a multidisciplinary setting. 
Conclusions
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Our analysis showed that in patients with low mediastinal 
lymph node involvement and resectable tumours a 
multimodal approach based on surgical resection is the 
preferred treatment practice in Switzerland, whereas 
with increasing mediastinal lymph node involvement, 
multimodal therapy based on radiation is being considered 
more frequently. Compared to recommended treatment 
pathways within international guidelines, surgery-based 
treatment for stage III N2 NSCLC in Switzerland is 
offered more extensively. Definitive evidence for the 
optimal treatment of resectable stage III N2 NSCLC 
remains elusive. The variability of recommendations among 
the participating sites may have multiple potential reasons. 
These may include local traditions (e.g., through the 
participation in the Swiss SAKK 16/00 trial investigation 
neoadjuvant radiochemotherapy in Stage IIIA N2 NSCLC), 
local technical equipment (ECMO), level of individual 
surgical or radiotherapy experience, incomplete definition 
of decision criteria (e.g., only broadly specified lymph 
node involvement, lacking definition of resectability) as 
well as different guideline used for development of local 
recommendation of the interdisciplinary tumour board. 
The different opinions reflected in the results of this 
manuscript reinforce the importance of a multidisciplinary 
setting and the importance of shared decision-making with 
the patient.
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